From the therapeutic standpoint, pRb cannot be a target of drugs, however, CDKs are therapeutic targets, and several generations of non-specific cell cycle CDKs inhibitors have been under clinical evaluation as cancer treatments with mixed results. The gene discussed is RB1; the disease is cancer.